Evidence map›Paper›PMID 30760000›Full record

ArticleCirculation2019

Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy.

Laura Benschop, Sarah Schalekamp-Timmermans, Zoe A Broere-Brown, Jeanine E Roeters van Lennep, Vincent W V Jaddoe, Jolien W Roos-Hesselink, M Kamran Ikram, Eric A P Steegers, James M Roberts, Robin E Gandley

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Late vs. Early Preeclampsia.International journal of molecular sciences · 2025
    Review
  10. ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disorders of pregnancy and fetal growth restriction.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025
    Article
  11. Article
  12. Novel biomarkers for preeclampsia: Promises and pitfalls.Current opinion in obstetrics & gynecology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Laura BenschopDepartments of Obstetrics and Gynecology (L.B., S.S.-T., Z.A.B.-B., E.A.P.S.), Erasmus Medical Center, Rotterdam, the Netherlands.
Sarah Schalekamp-TimmermansDepartments of Obstetrics and Gynecology (L.B., S.S.-T., Z.A.B.-B., E.A.P.S.), Erasmus Medical Center, Rotterdam, the Netherlands.
Zoe A Broere-BrownDepartments of Obstetrics and Gynecology (L.B., S.S.-T., Z.A.B.-B., E.A.P.S.), Erasmus Medical Center, Rotterdam, the Netherlands.
Jeanine E Roeters van LennepGeneral Medicine (J.E.R.v.L.), Erasmus Medical Center, Rotterdam, the Netherlands.
Vincent W V JaddoeEpidemiology (V.W.V.J.), Erasmus Medical Center, Rotterdam, the Netherlands.
Jolien W Roos-HesselinkCarCardiology (J.W.R.-H.), Erasmus Medical Center, Rotterdam, the Netherlands.
M Kamran IkramEpidemiology and Neurology (M.K.I.), Erasmus Medical Center, Rotterdam, the Netherlands.
Eric A P SteegersDepartments of Obstetrics and Gynecology (L.B., S.S.-T., Z.A.B.-B., E.A.P.S.), Erasmus Medical Center, Rotterdam, the Netherlands.
James M RobertsMagee-Womens Research Institute, Department of Obstetrics and Gynecology and Reproductive Sciences (J.M.R., R.E.G.), University of Pittsburgh, PA.
Robin E GandleyMagee-Womens Research Institute, Department of Obstetrics and Gynecology and Reproductive Sciences (J.M.R., R.E.G.), University of Pittsburgh, PA.
Erasmus MC · NLMagee-Womens Research Institute · US

Funding

TROPHOBLAST PRODUCTS IN GENESIS OF PREECLAMPSIAP01HD030367 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HUBEL, CARL A · 1993 to 2012
$17.2M
Glycocalyx in Pregnancy and the Preeclampsia SyndromeR21HD083659 · NICHD · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI GANDLEY, ROBIN E, HUBEL, CARL A · 2016 to 2017
$422k
NICHD NIH HHS P01 HD030367NICHD NIH HHS R21 HD083659
6 · The paper itself

Abstract

backgroundAngiogenic placental growth factor (PlGF) concentrations rise during pregnancy, peaking at the end of midpregnancy. Low PlGF concentrations during pregnancy are associated with pregnancy complications with recognized later-life cardiovascular risk. We hypothesized that low PlGF concentrations, especially in midpregnancy, identify not only a subset of women at risk for pregnancy complications but also women with greater cardiovascular risk factor burden after pregnancy regardless of pregnancy outcome.

methodsIn a population-based prospective cohort study of 5475 women, we computed gestational age-adjusted multiples of the medians of early pregnancy and midpregnancy PlGF concentrations. Information on pregnancy complications (preeclampsia, small for gestational age, and spontaneous preterm birth) was obtained from hospital registries. Six years after pregnancy, we measured maternal systolic and diastolic blood pressures, cardiac structure (aortic root diameter, left atrial diameter, left ventricular mass, and fractional shortening), carotid-femoral pulse wave velocity, and central retinal arteriolar and venular calibers. Blood pressure was also measured 9 years after pregnancy.

resultsWomen were on average 29.8 (SD, 5.2) years of age in pregnancy, were mostly European (55.2%), and 14.8% developed a pregnancy complication. Quartile analysis showed that especially women with midpregnancy PlGF in the lowest quartile (the low-PlGF subset) had a larger aortic root diameter (0.40 mm [95% CI, 0.08-0.73]), left atrial diameter (0.34 mm [95% CI, -0.09 to 0.78]), left ventricular mass (4.6 g [95% CI, 1.1-8.1]), and systolic blood pressure (2.3 mm Hg [95% CI, 0.93-3.6]) 6 years after pregnancy than women with the highest PlGF. Linear regression analysis showed that higher midpregnancy PlGF concentrations were associated with a smaller aortic root diameter (-0.24 mm [95% CI, -0.39 to -0.10]), smaller left atrial diameter (-0.75 mm [95% CI, -0.95 to -0.56]), lower left ventricular mass (-3.9 g [95% CI, -5.5 to -2.3]), and lower systolic blood pressure (-1.1 mm Hg [95% CI, -1.7 to -0.46]). These differences persisted after the exclusion of women with complicated pregnancies.

conclusionsWomen with low PlGF in midpregnancy have a greater aortic root diameter, left atrial diameter, and left ventricular mass and higher systolic blood pressure 6 and 9 years after pregnancy compared to women with higher PlGF, including women with uncomplicated pregnancies. The pathophysiological implications of lower PlGF concentrations in midpregnancy might provide insight into the identification of pathways contributing to greater cardiovascular risk factor burden.

Indexed as

Maternal HealthAdultBiomarkersCardiovascular DiseasesDown-RegulationFemaleHumansPlacenta Growth FactorPregnancyPregnancy ComplicationsPrognosisProspective StudiesRisk AssessmentRisk FactorsTime FactorsYoung AdultBiomarkersPGF protein, humanPlacenta Growth Factorcardiovascular diseasesplacenta growth factorpre-eclampsiapregnancy outcomerisk factors

Identifiers

PMID30760000
PMCPMC6443459
OpenAlexW2911963131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.